;PMID: 6708559
;source_file_2654.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..145] = [t:47..145]
;2)section:[e:149..170] = [t:149..170]
;3)sentence:[e:174..485] = [t:174..485]
;4)sentence:[e:487..696] = [t:487..696]
;5)sentence:[e:697..756] = [t:697..756]
;6)sentence:[e:757..889] = [t:757..889]
;7)sentence:[e:890..1075] = [t:890..1075]
;8)sentence:[e:1076..1215] = [t:1076..1215]
;9)sentence:[e:1216..1501] = [t:1216..1501]
;10)section:[e:1505..1549] = [t:1505..1549]

;section 0 Span:0..41
;J Steroid Biochem. 1984 Apr;20(4A):883-6.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (.:[17..18] .) (CD:[19..23] 1984) (::[24..31] Apr;20-LRB-)
        (NN:[31..33] 4A) (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..38] 883)
        (HYPH:[38..39] -) (CD:[39..41] 6.)))

;sentence 1 Span:47..145
;The support of steroid aromatization by mitochondrial metabolic activities of
; the human placenta.
;[62..69]:substance:"steroid"
(SENT
  (NP-HLN
    (NP (DT:[47..50] The) (NN:[51..58] support))
    (PP (IN:[59..61] of)
      (NP (NN:[62..69] steroid) (NN:[70..83] aromatization)))
    (PP (IN:[84..86] by)
      (NP
        (NP (JJ:[87..100] mitochondrial) (JJ:[101..110] metabolic)
            (NNS:[111..121] activities))
        (PP (IN:[122..124] of)
          (NP (DT:[126..129] the) (JJ:[130..135] human) (NN:[136..144] placenta)))))
    (.:[144..145] .)))

;section 2 Span:149..170
;Meigs RA, Moorthy KB.
(SEC
  (FRAG (NNP:[149..154] Meigs) (NNP:[155..157] RA) (,:[157..158] ,)
        (NNP:[159..166] Moorthy) (NNP:[167..170] KB.)))

;sentence 3 Span:174..485
;The role of mitochondrial hexokinase (EC 2.7.1.1.) and mitochondrial ATP 
;synthesis in the utilization of glucose for the support of estrogen
;biosynthesis  was examined in placental mitochondrial preparations
;supplemented with NADP+,  glucose-6-phosphate dehydrogenase (EC 1.1.1.49) and
;4-androstene-3,17-dione.
;[200..210]:substance:"hexokinase"
;[212..223]:substance:"EC 2.7.1.1."
;[243..246]:substance:"ATP"
;[280..287]:substance:"glucose"
;[307..315]:substance:"estrogen"
;[401..406]:substance:"NADP+"
;[409..442]:substance:"glucose-6-phosphate dehydrogenase"
;[444..455]:substance:"EC 1.1.1.49"
;[461..484]:substance:"4-androstene-3,17-dione"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[174..177] The) (NN:[178..182] role))
      (PP (IN:[183..185] of)
        (NP
          (NP
            (NP (JJ:[186..199] mitochondrial) (NN:[200..210] hexokinase))
            (NP (-LRB-:[211..212] -LRB-)
               (NN:[212..214] EC) (NN:[215..223] 2.7.1.1.)
              (-RRB-:[223..224] -RRB-)))
          (CC:[225..228] and)
          (NP (JJ:[229..242] mitochondrial) (NN:[243..246] ATP)
              (NN:[248..257] synthesis))))
      (PP (IN:[258..260] in)
        (NP
          (NP (DT:[261..264] the) (NN:[265..276] utilization))
          (PP (IN:[277..279] of)
            (NP (NN:[280..287] glucose)))
          (PP (IN:[288..291] for)
            (NP
              (NP (DT:[292..295] the) (NN:[296..303] support))
              (PP (IN:[304..306] of)
                (NP (NN:[307..315] estrogen) (NN:[316..328] biosynthesis))))))))
    (VP (VBD:[330..333] was)
      (VP (VBN:[334..342] examined)
        (NP-2 (-NONE-:[342..342] *))
        (PP-LOC (IN:[343..345] in)
          (NP
            (NP-1 (JJ:[346..355] placental) (JJ:[356..369] mitochondrial)
                  (NNS:[370..382] preparations))
            (VP (VBN:[383..395] supplemented)
              (NP-1 (-NONE-:[395..395] *))
              (PP (IN:[396..400] with)
                (NP
                  (NP (NN:[401..405] NADP) (SYM:[405..406] +))
                  (,:[406..407] ,)
                  (NP
                    (NP (NN:[409..428] glucose-6-phosphate)
                        (NN:[429..442] dehydrogenase))
                    (NP (-LRB-:[443..444] -LRB-)
                       (NN:[444..446] EC) (NN:[447..455] 1.1.1.49)
                      (-RRB-:[455..456] -RRB-)))
                  (CC:[457..460] and)
                  (NP (NN:[461..484] 4-androstene-3,17-dione)))))))))
    (.:[484..485] .)))

;sentence 4 Span:487..696
;With 14 mitochondrial preparations, rates of steroid aromatization supported
;by  100 mM glucose and 20 mM ATP had a mean of 65.7 +/- 7.1 (SD) % of rates
;achieved  with saturating levels of glucose 6-phosphate.
;[532..539]:substance:"steroid"
;[568..571]:quantitative-value:"100"
;[572..582]:quantitative-units:"mM glucose"
;[587..589]:quantitative-value:"20"
;[590..596]:quantitative-units:"mM ATP"
;[676..695]:substance:"glucose 6-phosphate"
(SENT
  (S
    (PP (IN:[487..491] With)
      (NP (CD:[492..494] 14) (JJ:[495..508] mitochondrial)
          (NNS:[509..521] preparations)))
    (,:[521..522] ,)
    (NP-SBJ
      (NP-2 (NNS:[523..528] rates))
      (PP (IN:[529..531] of)
        (NP (NN:[532..539] steroid) (NN:[540..553] aromatization)))
      (VP (VBN:[554..563] supported)
        (NP-2 (-NONE-:[563..563] *))
        (PP (IN:[564..566] by)
          (NP-LGS
            (NP
              (NML (CD:[568..571] 100) (NN:[572..574] mM))
              (NN:[575..582] glucose))
            (CC:[583..586] and)
            (NP
              (NML (CD:[587..589] 20) (NN:[590..592] mM))
              (NN:[593..596] ATP))))))
    (VP (VBD:[597..600] had)
      (NP
        (NP (DT:[601..602] a) (NN:[603..607] mean))
        (PP (IN:[608..610] of)
          (NP
            (NP
              (QP (CD:[611..615] 65.7) (SYM:[616..619] +/-) (CD:[620..623] 7.1))
              (PRN (-LRB-:[624..625] -LRB-)
                (NML (NN:[625..627] SD))
                (-RRB-:[627..628] -RRB-))
              (NN:[629..630] %))
            (PP (IN:[631..633] of)
              (NP
                (NP-1 (NNS:[634..639] rates))
                (VP (VBN:[640..648] achieved)
                  (NP-1 (-NONE-:[648..648] *))
                  (PP (IN:[650..654] with)
                    (NP
                      (NP (VBG:[655..665] saturating) (NNS:[666..672] levels))
                      (PP (IN:[673..675] of)
                        (NP (NN:[676..683] glucose) (NN:[684..695] 6-phosphate))))))))))))
    (.:[695..696] .)))

;sentence 5 Span:697..756
;ADP, but not AMP, could  substitute for ATP in this system.
;[697..700]:substance:"ADP"
;[710..713]:substance:"AMP"
;[737..740]:substance:"ATP"
(SENT
  (S
    (NP-SBJ (NN:[697..700] ADP) (,:[700..701] ,)
      (CONJP (CC:[702..705] but) (RB:[706..709] not))
      (NN:[710..713] AMP))
    (,:[713..714] ,)
    (VP (MD:[715..720] could)
      (VP (VB:[722..732] substitute)
        (PP (IN:[733..736] for)
          (NP (NN:[737..740] ATP)))
        (PP-LOC (IN:[741..743] in)
          (NP (DT:[744..748] this) (NN:[749..755] system)))))
    (.:[755..756] .)))

;sentence 6 Span:757..889
;Aromatization supported by glucose and high  concentrations of ADP was
;inhibited by AMP but not by 2,4-dinitrophenol or  oligomycin.
;[784..791]:substance:"glucose"
;[820..823]:substance:"ADP"
;[841..844]:substance:"AMP"
;[856..873]:substance:"2,4-dinitrophenol"
;[878..888]:substance:"oligomycin"
(SENT
  (S
    (NP-SBJ-4
      (NP-3 (NN:[757..770] Aromatization))
      (VP (VBN:[771..780] supported)
        (NP-3 (-NONE-:[780..780] *))
        (PP (IN:[781..783] by)
          (NP-LGS
            (NP (NN:[784..791] glucose))
            (CC:[792..795] and)
            (NP
              (NP (JJ:[796..800] high) (NNS:[802..816] concentrations))
              (PP (IN:[817..819] of)
                (NP (NN:[820..823] ADP))))))))
    (VP (VBD:[824..827] was)
      (VP (VBN:[828..837] inhibited)
        (NP-4 (-NONE-:[837..837] *))
        (PP=2 (IN:[838..840] by)
          (NP-LGS (NN:[841..844] AMP))))
      (CC:[845..848] but)
      (VP (RB:[849..852] not)
        (NP-4 (-NONE-:[852..852] *))
        (PP=2 (IN:[853..855] by)
          (NP-LGS
            (NP (NN:[856..873] 2,4-dinitrophenol))
            (CC:[874..876] or)
            (NP (NN:[878..888] oligomycin))))))
    (.:[888..889] .)))

;sentence 7 Span:890..1075
;Glucose also supported mitochondrial aromatization when combined  with a
;respiratory chain-linked metabolic substrate (glycerol 3-phosphate) and a 
;limiting concentration of ADP (2 mM).
;[890..897]:substance:"Glucose"
;[998..1007]:substance:"substrate"
;[1009..1029]:substance:"glycerol 3-phosphate"
;[1064..1067]:substance:"ADP"
;[1069..1070]:quantitative-value:"2"
;[1071..1073]:quantitative-units:"mM"
(SENT
  (S
    (NP-SBJ (NN:[890..897] Glucose))
    (ADVP (RB:[898..902] also))
    (VP (VBD:[903..912] supported)
      (NP (JJ:[913..926] mitochondrial) (NN:[927..940] aromatization))
      (SBAR-ADV
        (WHADVP-1 (WRB:[941..945] when))
        (S
          (NP-SBJ (-NONE-:[945..945] *))
          (VP (VBN:[946..954] combined)
            (PP-CLR (IN:[956..960] with)
              (NP
                (NP
                  (NP (DT:[961..962] a) (JJ:[963..974] respiratory)
                    (ADJP (NN:[975..980] chain) (HYPH:[980..981] -)
                          (VBN:[981..987] linked))
                    (JJ:[988..997] metabolic) (NN:[998..1007] substrate))
                  (NP (-LRB-:[1008..1009] -LRB-)
                     (NN:[1009..1017] glycerol) (NN:[1018..1029] 3-phosphate)
                    (-RRB-:[1029..1030] -RRB-)))
                (CC:[1031..1034] and)
                (NP
                  (NP (DT:[1035..1036] a) (VBG:[1038..1046] limiting)
                      (NN:[1047..1060] concentration))
                  (PP (IN:[1061..1063] of)
                    (NP (NN:[1064..1067] ADP)))
                  (PRN (-LRB-:[1068..1069] -LRB-)
                    (NP (CD:[1069..1070] 2) (NN:[1071..1073] mM))
                    (-RRB-:[1073..1074] -RRB-)))))
            (ADVP-1 (-NONE-:[1074..1074] *T*))))))
    (.:[1074..1075] .)))

;sentence 8 Span:1076..1215
;This support was inhibited by  2,4-dinitrophenol, the
;p-trifluoromethoxyphenylhydrazone of carbonyl cyanide,  oligomycin and
;atractyloside.
;[1107..1124]:substance:"2,4-dinitrophenol"
;[1130..1163]:substance:"p-trifluoromethoxyphenylhydrazone"
;[1167..1183]:substance:"carbonyl cyanide"
;[1186..1196]:substance:"oligomycin"
;[1201..1214]:substance:"atractyloside"
(SENT
  (S
    (NP-SBJ-1 (DT:[1076..1080] This) (NN:[1081..1088] support))
    (VP (VBD:[1089..1092] was)
      (VP (VBN:[1093..1102] inhibited)
        (NP-1 (-NONE-:[1102..1102] *))
        (PP (IN:[1103..1105] by)
          (NP-LGS
            (NP (NN:[1107..1124] 2,4-dinitrophenol))
            (,:[1124..1125] ,)
            (NP
              (NP (DT:[1126..1129] the)
                  (NN:[1130..1163] p-trifluoromethoxyphenylhydrazone))
              (PP (IN:[1164..1166] of)
                (NP (NN:[1167..1175] carbonyl) (NN:[1176..1183] cyanide))))
            (,:[1183..1184] ,)
            (NP (NN:[1186..1196] oligomycin))
            (CC:[1197..1200] and)
            (NP (NN:[1201..1214] atractyloside))))))
    (.:[1214..1215] .)))

;sentence 9 Span:1216..1501
;Thus, glucose metabolism by mitochondrial  hexokinase, utilizing ATP
;generated either by oxidative phosphorylation or  mitochondrial adenylate
;kinase (EC 2.7.4.3), can be coupled with a soluble  NADPH-generating system
;to provide effective support of mitochondrial estrogen  synthesis.
;[1222..1229]:substance:"glucose"
;[1259..1269]:substance:"hexokinase"
;[1281..1284]:substance:"ATP"
;[1349..1365]:substance:"adenylate kinase"
;[1367..1377]:substance:"EC 2.7.4.3"
;[1411..1416]:substance:"NADPH"
;[1481..1489]:substance:"estrogen"
(SENT
  (S
    (ADVP (RB:[1216..1220] Thus))
    (,:[1220..1221] ,)
    (NP-SBJ-2
      (NP (NN:[1222..1229] glucose) (NN:[1230..1240] metabolism))
      (PP (IN:[1241..1243] by)
        (NP (JJ:[1244..1257] mitochondrial) (NN:[1259..1269] hexokinase)))
      (,:[1269..1270] ,)
      (VP (VBG:[1271..1280] utilizing)
        (NP
          (NP (NN:[1281..1284] ATP))
          (VP (VBN:[1285..1294] generated)
            (NP (-NONE-:[1294..1294] *))
            (PP (CC:[1295..1301] either) (IN:[1302..1304] by)
              (NP-LGS
                (NP (JJ:[1305..1314] oxidative)
                    (NN:[1315..1330] phosphorylation))
                (CC:[1331..1333] or)
                (NP (JJ:[1335..1348] mitochondrial)
                   (NN:[1349..1358] adenylate) (NN:[1359..1365] kinase))
                (PRN (-LRB-:[1366..1367] -LRB-)
                  (NP (NN:[1367..1369] EC) (NN:[1370..1377] 2.7.4.3))
                  (-RRB-:[1377..1378] -RRB-))))))))
    (,:[1378..1379] ,)
    (VP (MD:[1380..1383] can)
      (VP (VB:[1384..1386] be)
        (VP (VBN:[1387..1394] coupled)
          (NP-2 (-NONE-:[1394..1394] *))
          (PP-CLR (IN:[1395..1399] with)
            (NP (DT:[1400..1401] a) (JJ:[1402..1409] soluble)
              (ADJP (NN:[1411..1416] NADPH) (HYPH:[1416..1417] -)
                    (VBG:[1417..1427] generating))
              (NN:[1428..1434] system)))
          (S-ADV
            (NP-SBJ (-NONE-:[1434..1434] *))
            (VP (TO:[1435..1437] to)
              (VP (VB:[1438..1445] provide)
                (NP
                  (NP (JJ:[1446..1455] effective) (NN:[1456..1463] support))
                  (PP (IN:[1464..1466] of)
                    (NP (JJ:[1467..1480] mitochondrial)
                        (NN:[1481..1489] estrogen) (NN:[1491..1500] synthesis))))))))))
    (.:[1500..1501] .)))

;section 10 Span:1505..1549
;PMID: 6708559 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1505..1509] PMID) (::[1509..1510] :) (CD:[1511..1518] 6708559)
        (NN:[1519..1520] -LSB-) (NNP:[1520..1526] PubMed) (::[1527..1528] -)
        (NN:[1529..1536] indexed) (IN:[1537..1540] for)
        (NNP:[1541..1549] MEDLINE-RSB-)))
